Qualigen Therapeutics, Inc.
QLGN
$3.11
$0.103.32%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | 1.63M | 3.23M | 4.62M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | 1.63M | 3.23M | 4.62M |
| Cost of Revenue | 2.55M | 3.87M | 4.29M | 5.21M | 4.77M |
| Gross Profit | -2.55M | -3.87M | -4.29M | -5.21M | -4.77M |
| SG&A Expenses | 4.15M | 4.34M | 5.78M | 6.10M | 7.70M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.71M | 8.21M | 10.08M | 11.30M | 12.47M |
| Operating Income | -6.71M | -8.21M | -10.08M | -11.30M | -12.47M |
| Income Before Tax | -7.78M | -9.22M | -11.27M | -12.47M | -13.60M |
| Income Tax Expenses | -6.40K | -4.20K | 1.00K | 600.00 | 5.80K |
| Earnings from Continuing Operations | -7.77 | -9.21 | -11.27 | -12.48 | -13.61 |
| Earnings from Discontinued Operations | -82.70K | -504.20K | -331.00K | -942.20K | -3.73M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -7.85M | -9.72M | -11.60M | -13.42M | -17.34M |
| EBIT | -6.71M | -8.21M | -10.08M | -11.30M | -12.47M |
| EBITDA | -6.70M | -8.15M | -9.95M | -11.12M | -12.28M |
| EPS Basic | -56.11 | -87.60 | -111.52 | -132.69 | -184.84 |
| Normalized Basic EPS | -28.64 | -45.10 | -60.79 | -66.36 | -82.00 |
| EPS Diluted | -56.15 | -87.64 | -111.55 | -132.73 | -184.93 |
| Normalized Diluted EPS | -28.64 | -45.10 | -60.79 | -66.36 | -82.00 |
| Average Basic Shares Outstanding | 763.40K | 476.50K | 425.40K | 405.70K | 385.50K |
| Average Diluted Shares Outstanding | 763.40K | 476.50K | 425.40K | 405.70K | 385.50K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
